References
- Cohen A M, Minsky B D, Schilsky R L. Colon cancer. Cancer: Principles and Practice of Oncology, 4th ed, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1993
- Laurie J A, Moertel C G, Fleming T R, Wieand H S, Leigh J E, Robin J. Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole, and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 10: 1447–1456
- Moenel C G, Fleming T R, MacDonald J S, Haller D G, Laurie J A, Goodman P J. Levamisole and fluorouracil for adjuvant therapy of colon carcinoma. N Engl J Med 1990; 322: 352–358
- Hook C C, Kimmel D W, Kvols L K, Scheithauer B W, Forsyth P A, Robin J. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–267
- Neu I S, Ober H. Multifocal leukoencephalopathy following adjuvant therapy with fluorouracil and levamisole. Dtsch Med Wochenschr 1992; 117: 1379
- Leichman L, Brown T, Poplin B. Symptomatic, radiologic and pathologic changes in the central nervous system associated with 5-fluorouracil and levamisole therapy. Proc Am Soc Clin Oncol 1993; 12: 198, (abstract)
- Stevenson H C, Green I, Hamilton J M, Calabro B A, Parkinson D R. Levamisole: Known effects on the immune system, clinical results. and future applications to the treatment of cancer. J Clin Oncol 1991; 9: 2052–2066
- Symoens J, Veys E, Mielans M, Pinals R. Adverse reactions to levamisole. Cancer Treat Rep 1978; 62: 1721–1730
- Grem J L. Fluorinated pyrimidines. Cancer Chemotherapy, BA Chabner, JM Collins. JB Lippincott, Philadelphia 1990; 180–224
- Moore DH., Fowler W C, Crumpler L S. 5-Fluorouracil neurotox-icity. Gynecol Oncol 1990; 36: 152–154
- Greenwald E S. Organic mental changes with 5-tluorouracil therapy. JAMA 1976; 235: 248–249
- Lynch HT., Droszcz C P, Albano W A, Lynch J F. “Organic brain syndrome” secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981; 24: 130–131